Safety and efficacy of peripheral metaraminol infusion in patients with neurological conditions: a single-center retrospective observational study

Pan Han, Yu Zhou
{"title":"Safety and efficacy of peripheral metaraminol infusion in patients with neurological conditions: a single-center retrospective observational study","authors":"Pan Han, Yu Zhou","doi":"10.3389/fneur.2024.1398827","DOIUrl":null,"url":null,"abstract":"Metaraminol is a sympathomimetic amine vasopressor that can be administrated through a peripheral venous access. However, limited evidence restricts its application in critically ill patients. This study aimed to investigate the safety and efficacy of peripheral metaraminol infusion in patients with neurological conditions.Patients who received peripheral metaraminol infusion between May 2019 and April 2022 were recruited. Data on baseline characteristics, clinical parameters, and infusion-related complications were retrospectively collected and analyzed.273 patients who received metaraminol were enrolled. Of these, 35 (12.8%) patients required central venous catheter insertion due to inability in achieving hemodynamic stability following peripheral metaraminol monotherapy. In 29,574.2 hours of vasopressor infusion, metaraminol infusion resulted achievement of the target blood pressure 73.4% of the time. Meanwhile, adverse events occurred in 5 patients and resolved after local tissue treatment.Metaraminol could provide hemodynamic support and avoid complications associated with a central venous catheter and delay in vasopressor administration. Through careful and close monitoring, peripheral metaraminol infusion is safe and feasible for patients with neurological conditions. Future large-scale, prospective, multicenter studies are needed to evaluate the safety and efficacy of metaraminol infusion through a peripheral intravenous catheter.","PeriodicalId":503840,"journal":{"name":"Frontiers in Neurology","volume":"47 12","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fneur.2024.1398827","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Metaraminol is a sympathomimetic amine vasopressor that can be administrated through a peripheral venous access. However, limited evidence restricts its application in critically ill patients. This study aimed to investigate the safety and efficacy of peripheral metaraminol infusion in patients with neurological conditions.Patients who received peripheral metaraminol infusion between May 2019 and April 2022 were recruited. Data on baseline characteristics, clinical parameters, and infusion-related complications were retrospectively collected and analyzed.273 patients who received metaraminol were enrolled. Of these, 35 (12.8%) patients required central venous catheter insertion due to inability in achieving hemodynamic stability following peripheral metaraminol monotherapy. In 29,574.2 hours of vasopressor infusion, metaraminol infusion resulted achievement of the target blood pressure 73.4% of the time. Meanwhile, adverse events occurred in 5 patients and resolved after local tissue treatment.Metaraminol could provide hemodynamic support and avoid complications associated with a central venous catheter and delay in vasopressor administration. Through careful and close monitoring, peripheral metaraminol infusion is safe and feasible for patients with neurological conditions. Future large-scale, prospective, multicenter studies are needed to evaluate the safety and efficacy of metaraminol infusion through a peripheral intravenous catheter.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
神经系统疾病患者输注外周美他胺醇的安全性和有效性:一项单中心回顾性观察研究
美他胺醇是一种拟交感胺类血管抑制剂,可通过外周静脉通路给药。然而,有限的证据限制了其在重症患者中的应用。本研究旨在调查外周美他胺醇输注在神经系统疾病患者中的安全性和有效性,招募了2019年5月至2022年4月期间接受外周美他胺醇输注的患者。对基线特征、临床参数和输注相关并发症的数据进行了回顾性收集和分析。其中,35 例(12.8%)患者因外周美他明醇单药治疗后无法实现血流动力学稳定而需要插入中心静脉导管。在 29574.2 小时的血管舒张剂输注过程中,73.4% 的患者在输注美他胺醇后达到了目标血压。美他胺醇可提供血流动力学支持,并避免中心静脉导管和血管加压剂输注延迟带来的并发症。通过仔细严密的监测,外周输注美他胺醇对神经系统疾病患者是安全可行的。未来需要进行大规模、前瞻性、多中心研究,以评估通过外周静脉导管输注甲氨醇的安全性和有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Stem cell therapy: a new hope for stroke and traumatic brain injury recovery and the challenge for rural minorities in South Carolina NORSE/FIRES: how can we advance our understanding of this devastating condition? Multiple sclerosis in LRRK2 G2019S Parkinson’s disease and isolated nigral degeneration in a homozygous variant carrier Effectiveness of active middle ear implant placement methods in pathological conditions: basilar membrane vibration simulation Risk factors of in-stent restenosis after carotid angioplasty and stenting: long-term follow-up study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1